Adenosquamous Carcinoma

Categories: Cancer diseases, Endocrine diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Adenosquamous Carcinoma

MalaCards integrated aliases for Adenosquamous Carcinoma:

Name: Adenosquamous Carcinoma 11 14 16 71 75
Mixed Adenocarcinoma and Squamous Carcinoma 11
Adenosquamous Cell Carcinoma 11
Carcinoma, Adenosquamous 43
Carcinoma Adenosquamous 53


External Ids:

Disease Ontology 11 DOID:4830
MeSH 43 D018196
NCIt 49 C3727
SNOMED-CT 68 403902008
UMLS 71 C0206623

Summaries for Adenosquamous Carcinoma

Disease Ontology: 11 A squamous cell carcinoma that contains squamous cells and gland-like cells.

MalaCards based summary: Adenosquamous Carcinoma, also known as mixed adenocarcinoma and squamous carcinoma, is related to adenosquamous gallbladder carcinoma and esophageal adenosquamous carcinoma. An important gene associated with Adenosquamous Carcinoma is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are COPI-independent Golgi-to-ER retrograde traffic and Keratinization. The drugs Topotecan and Gemcitabine have been mentioned in the context of this disorder. Affiliated tissues include pancreas, cervix and lung, and related phenotypes are homeostasis/metabolism and growth/size/body region

Wikipedia: 75 Adenosquamous carcinoma is a type of cancer that contains two types of cells: squamous cells (thin, flat... more...

Related Diseases for Adenosquamous Carcinoma

Diseases related to Adenosquamous Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 646)
# Related Disease Score Top Affiliating Genes
1 adenosquamous gallbladder carcinoma 32.7 KRT7 KRT5 KRT19
2 esophageal adenosquamous carcinoma 32.6 KRT7 KRT5 CEACAM5
3 vaginal cancer 32.2 PGR KRT7 EGFR
4 adenosquamous bile duct carcinoma 32.2 KRT7 KRT19 CEACAM5
5 breast metaplastic carcinoma 31.1 PGR KRT7 KRT5
6 gallbladder adenocarcinoma 31.0 MUC5AC MUC1 KRT7 CHGA CEACAM5
7 adenoid squamous cell carcinoma 31.0 KRT8 KRT7 KRT5 KRT19 CEACAM5
8 squamous cell carcinoma 30.9 TP63 PTHLH NKX2-1 MUC1 KRT7 KRT19
9 cervix carcinoma 30.9 PGR KRT7 EGFR CEACAM5
10 lung squamous cell carcinoma 30.8 PTHLH KRT19 EGFR CEACAM5
11 adenocarcinoma 30.8 NKX2-1 MUC5AC MUC4 MUC1 KRT7 KRT20
12 rectum cancer 30.8 KRT20 EGFR CEACAM7 CEACAM5
13 intrahepatic cholangiocarcinoma 30.8 MUC4 KRT7 KRT19 EGFR CEACAM5
14 cervical squamous cell carcinoma 30.7 TP63 KRT8 EGFR CEACAM5
15 cervical adenocarcinoma 30.7 PGR MUC5AC KRT8 KRT7 KRT20 CEACAM7
16 endometrial adenocarcinoma 30.7 PGR KRT7 EGFR
17 endometrial cancer 30.7 PGR MUC1 KRT7 KRT20 KDR EGFR
18 lip and oral cavity cancer 30.7 KRT19 IVL EGFR
19 rectal benign neoplasm 30.6 KRT7 KRT20 EGFR CEACAM5
20 gastric adenocarcinoma 30.6 MUC4 KRT20 CHGA CEACAM5
21 carcinosarcoma 30.6 PGR MUC1 KRT7 EGFR
22 mucoepidermoid carcinoma 30.6 TP63 MUC5AC MUC4 MUC1 KRT8 KRT7
23 appendix adenocarcinoma 30.6 KRT7 KRT20 CHGA CEACAM5
24 bile duct cysts 30.6 KRT7 KRT19 CEACAM5
25 klatskin's tumor 30.6 KRT7 KRT19 CEACAM5
26 cholangiocarcinoma 30.5 MUC5AC MUC4 MUC1 KRT8 KRT7 KRT20
27 ampulla of vater cancer 30.5 MUC5AC MUC1 KRT7 KRT20 EGFR CEACAM5
28 small cell cancer of the lung 30.5 NKX2-1 KRT7 KRT20 EGFR CHGA CEACAM5
29 teratoma 30.5 NKX2-1 MUC1 KRT7 KRT20 CHGA CEACAM5
30 keratinizing squamous cell carcinoma 30.5 NKX2-1 KRT7 KRT5 EGFR CEACAM5
31 endocervical adenocarcinoma 30.5 PGR KRT7 CEACAM5
32 papillary adenocarcinoma 30.5 NKX2-1 MUC1 KRT7 KRT5 CEACAM5
33 gallbladder cancer 30.5 MUC5AC MUC1 KRT8 KRT7 KRT20 KRT19
34 cystic teratoma 30.5 NKX2-1 MUC1 KRT7 KRT20 CHGA CEACAM5
35 keratoacanthoma 30.5 TP63 KRT8 KRT19 IVL EGFR
36 necrotizing sialometaplasia 30.4 KRT7 KRT5
37 breast fibroadenoma 30.4 PGR KRT8 KRT5 EGFR
38 skin benign neoplasm 30.4 TP63 KRT7 KRT5 KRT20
39 mucoepidermoid esophageal carcinoma 30.4 KRT5 CEACAM5
40 adenosquamous breast carcinoma 30.4 PGR KRT5
41 papilloma 30.4 TP63 KRT8 KRT7 KRT5 KRT20 IVL
42 gastric squamous cell carcinoma 30.4 KRT7 KRT5
43 anal canal carcinoma 30.4 KRT7 KRT5 KRT20 CEACAM5
44 benign teratoma 30.4 NKX2-1 KRT7 KRT5 KRT20 CHGA CEACAM5
45 colorectal adenocarcinoma 30.4 KRT7 KRT20 EGFR CEACAM5
46 lung benign neoplasm 30.4 NKX2-1 KRT7 KRT20 EGFR CHGA
47 bronchus cancer 30.4 KRT7 EGFR CEACAM5
48 adenoma 30.4 MUC5AC MUC1 KRT7 KRT20 KRT19 CHGA
49 small cell carcinoma 30.4 NKX2-1 KRT7 KRT5 KRT20 EGFR CHGA
50 intestinal obstruction 30.4 KRT7 KRT20 CEACAM5

Graphical network of the top 20 diseases related to Adenosquamous Carcinoma:

Diseases related to Adenosquamous Carcinoma

Symptoms & Phenotypes for Adenosquamous Carcinoma

MGI Mouse Phenotypes related to Adenosquamous Carcinoma:

45 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.37 CEACAM5 CEACAM7 CHGA EGFR KDR KRT7
2 growth/size/body region MP:0005378 10.32 CEACAM5 CEACAM7 CHGA EGFR IVL KDR
3 normal MP:0002873 10.26 CEACAM7 EGFR IVL KDR KRT19 MUC1
4 neoplasm MP:0002006 10.24 CEACAM5 EGFR KRT19 MUC1 MUC4 NKX2-1
5 digestive/alimentary MP:0005381 10.21 CEACAM5 EGFR KRT19 KRT5 KRT8 MUC1
6 no phenotypic analysis MP:0003012 10.16 CHGA EGFR KDR KRT19 MUC1 NKX2-1
7 endocrine/exocrine gland MP:0005379 10.16 CEACAM5 CHGA EGFR KRT19 MUC1 NKX2-1
8 cardiovascular system MP:0005385 10.15 CEACAM5 CHGA EGFR IVL KDR KRT19
9 immune system MP:0005387 10.13 CEACAM5 CEACAM7 EGFR KDR KRT19 KRT5
10 craniofacial MP:0005382 9.95 EGFR KDR KRT19 KRT5 PDGFRA PTHLH
11 respiratory system MP:0005388 9.86 EGFR KDR KRT19 MUC4 NKX2-1 PDGFRA
12 reproductive system MP:0005389 9.85 CHGA EGFR IVL KRT19 KRT8 NKX2-1
13 mortality/aging MP:0010768 9.8 CEACAM5 CEACAM7 CHGA EGFR KDR KRT19
14 integument MP:0010771 9.32 CEACAM7 EGFR KDR KRT19 KRT5 MUC1

Drugs & Therapeutics for Adenosquamous Carcinoma

Drugs for Adenosquamous Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 120)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Topotecan Approved, Investigational Phase 3 123948-87-8, 119413-54-6 60699 60700
Gemcitabine Approved Phase 3 95058-81-4, 122111-03-9 60750
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
Vinorelbine Approved, Investigational Phase 3 71486-22-1 44424639 60780
Ipilimumab Approved Phase 2, Phase 3 477202-00-9
Pembrolizumab Approved Phase 2, Phase 3 1374853-91-4 254741536
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 43805 11947679 6857599
Cisplatin Approved Phase 3 15663-27-1 2767 5702198 441203
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
Carboplatin Approved Phase 3 41575-94-4 10339178 38904
Erlotinib Approved, Investigational Phase 3 183319-69-9, 183321-74-6 176870
Tirapazamine Investigational Phase 3 27314-97-2 135413511
13 Antiviral Agents Phase 3
14 Antimetabolites Phase 3
Epoetin Alfa Phase 3
16 Hematinics Phase 3
17 Chrysarobin Phase 3
18 Liposomal doxorubicin Phase 3
19 Vitamins Phase 3
20 Hormones Phase 3
21 Trace Elements Phase 3
22 topoisomerase I inhibitors Phase 3
23 Antidotes Phase 3
24 Calcium, Dietary Phase 3
25 Micronutrients Phase 3
26 Protective Agents Phase 3
27 Albumin-Bound Paclitaxel Phase 3
28 Immunoglobulins Phase 3
29 Antimitotic Agents Phase 3
30 Tubulin Modulators Phase 3
31 Antibodies, Monoclonal Phase 3
32 Antibodies Phase 3
33 Mitogens Phase 3
34 Protein Kinase Inhibitors Phase 3
35 Insulin, Globin Zinc Phase 3
Insulin Phase 3
Calcium Nutraceutical Phase 3 7440-70-2 271
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
Medroxyprogesterone acetate Approved, Investigational Phase 2 520-85-4, 71-58-9 6279 10631
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
Sunitinib Approved, Investigational Phase 2 557795-19-4 5329102
Thalidomide Approved, Investigational, Withdrawn Phase 2 50-35-1 5426
Metformin Approved Phase 2 1115-70-4, 657-24-9 4091
Olaparib Approved Phase 2 763113-22-0 23725625
Coenzyme M Approved, Investigational Phase 2 3375-50-6 598 23662354
Bevacizumab Approved, Investigational Phase 2 216974-75-3 135329020
Nivolumab Approved Phase 2 946414-94-4
Lenograstim Approved, Investigational Phase 2 135968-09-1
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189

Interventional clinical trials:

(show top 50) (show all 79)
# Name Status NCT ID Phase Drugs
1 A Randomized Phase III Trial of Cisplatin Plus Paclitaxel With and Without NCI-Supplied Bevacizumab (NSC #704865) Versus the Non-platinum Doublet, Topotecan Plus Paclitaxel, With and Without NCI-Supplied Bevacizumab, in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix Completed NCT00803062 Phase 3 Cisplatin;Paclitaxel;Topotecan Hydrochloride
2 Phase III Trial to Evaluate the Efficacy of Maintaining Hemoglobin Levels Above 120 g/l With Erythropoietin Versus Above 100 g/l Without Erythropoietin in Anemic Patients Receiving Concurrent Radiation and Cisplatin for Cervical Cancer Completed NCT00017004 Phase 3 Cisplatin
3 A Randomized Phase III Trial Of Paclitaxel Plus Cisplatin Versus Vinorelbine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Versus Topotecan Plus Cisplatin In Stage IVB, Recurrent Or Persistent Carcinoma of the Cervix Completed NCT00064077 Phase 3 Cisplatin;Gemcitabine Hydrochloride;Paclitaxel;Topotecan Hydrochloride;Vinorelbine Tartrate
4 A Randomized Phase III Study of Tumor Volume Directed Pelvic Plus or Minus Para-Aortic Irradiation Followed by Cisplatin and Doxorubicin or Cisplatin, Doxorubicin and Paclitaxel for Advanced Endometrial Carcinoma Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
5 A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial Completed NCT01414608 Phase 3 Carboplatin;Cisplatin;Paclitaxel
6 A Phase III Randomized Study of Pretherapeutic Para-aortic Lymphadenectomy in Women With Locally Advanced Cervical Cancer Dispositioned to Definitive Chemoradiotherapy Completed NCT01365156 Phase 3
7 A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy With or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer Recruiting NCT04929041 Phase 2, Phase 3 Carboplatin;Nab-paclitaxel;Paclitaxel;Pemetrexed
8 A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer Recruiting NCT04340141 Phase 3 Oxaliplatin;Irinotecan Hydrochloride;Leucovorin Calcium;Fluorouracil
9 A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer Active, not recruiting NCT02466971 Phase 3 Cisplatin;Triapine
10 Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451) Active, not recruiting NCT01101451 Phase 3 Cisplatin
11 PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer. Not yet recruiting NCT05581121 Phase 3
12 Randomized Phase III Trial Evaluating the Impact of Hysterectomy After Chemoradiation Therapy for Stage IB2/II Cervical Cancer Terminated NCT01363466 Phase 3
13 A Phase III, Randomized Trial of Weekly Cisplatin and Radiation Versus Cisplatin and Tirapazamine and Radiation in Stage IB2, IIA, IIIB and IVA Cervical Carcinoma Limited to the Pelvis Terminated NCT00262821 Phase 3 cisplatin;tirapazamine
14 Randomized, Open Label, Phase 3 Trial Of Erlotinib Alone Or In Combination With CP-751,871 In Patients With Advanced Non Small Cell Lung Cancer Of Non Adenocarcinoma Histology Terminated NCT00673049 Phase 3 CP 751,871 (Figitumumab);Erlotinib
15 Randomized, Open Label, Phase III Trial Of CP- 751,871 In Combination With Paclitaxel And Carboplatin Versus Paclitaxel And Carboplatin In Patients With Non Small Cell Lung Cancer Terminated NCT00596830 Phase 3 CP-751,871 (Figitumumab);Carboplatin;Paclitaxel
16 Efficacy and Safety of Nimotuzumab Combined With Radiotherapy and Concurrently Cisplatin in Patients With Stage IIB-IVA Cervical Squamous Cell Carcinoma Unknown status NCT03469531 Phase 2 Nimotuzumab;Cisplatin
18 A Phase II Evaluation of Gemcitabine (Gemzar®, LY188011) in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT00820898 Phase 2 Gemcitabine Hydrochloride
19 A Phase II Study of Postoperative Intensity Modulated Radiation Therapy (IMRT) With Concurrent Cisplatin and Bevacizumab Followed by Carboplatin and Paclitaxel for Patients With Endometrial Cancer Completed NCT01005329 Phase 2 Carboplatin;Cisplatin;Paclitaxel
20 A Phase II Pilot Investigation Of The Relationship Of Short Term Depo-Provera (Medroxyprogesterone Acetate) Exposure To The Morphologic , Biochemical, And Molecular Changes In Primary Endometroid Adenocarcinoma of the Uterine Corpus Completed NCT00064025 Phase 2 Medroxyprogesterone
21 A Phase II Evaluation Of Capecitabine (NSC #712807) In The Treatment Of Persistent Or Recurrent Non-Squamous Cell Carcinoma Of The Cervix Completed NCT00039442 Phase 2 Capecitabine
22 A Phase II Evaluation of AZD6244 (NSC #748727) in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01011933 Phase 2 Selumetinib
23 A Phase II Evaluation of Cediranib (Recentin; AZD2171, IND#72740, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01132820 Phase 2 Cediranib Maleate
24 A Phase II Study of Oxaliplatin in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Cervical Cancer Completed NCT00057863 Phase 2 Paclitaxel;Oxaliplatin
25 Prospective Evaluation of Pelvic Exenteration in Patients With Recurrent Cervical Cancer Completed NCT00217633 Phase 2
26 A Phase II Evaluation of ABI-007 in the Treatment of Persistent or Recurrent Squamous or Nonsquamous Cell Carcinoma of the Cervix Completed NCT00309959 Phase 2 Paclitaxel Albumin-Stabilized Nanoparticle Formulation
27 A Phase II Randomized Study of OSI-774 (Erlotinib) (NSC #718781) With or Without Carboplatin/Paclitaxel in Patients With Previously Untreated Adenocarcinoma of the Lung Who Never Smoked or Were Former Light Smokers Completed NCT00126581 Phase 2 Carboplatin;Erlotinib;Erlotinib Hydrochloride;Paclitaxel
28 A Phase II Study of Temsirolimus (NSC 683864), an mTOR Inhibitor, in Patients With Recurrent, Unresectable, Locally Advanced or Metastatic Carcinoma of the Cervix Completed NCT01026792 Phase 2 Temsirolimus
29 A Phase II Evaluation of ADXS11-001 (NSC 752718) in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix Completed NCT01266460 Phase 2
30 A Phase II Evaluation of ABT-888 (NCI Supplied Agent: ABT-888, NSC #737664), Topotecan (NSC # 609699) and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Squamous or Non-squamous Cell Carcinoma of the Cervix Completed NCT01266447 Phase 2 Topotecan Hydrochloride;Veliparib
31 A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048) Completed NCT01267253 Phase 2 Brivanib Alaninate
32 A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer Completed NCT02921269 Phase 2 Atezolizumab
33 A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium Completed NCT01210222 Phase 2
34 A Phase II, 2-Stage, 2-Arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer Completed NCT01307631 Phase 2 Akt Inhibitor MK2206
35 Phase II Clinical Trial of Bryostatin-1, NSC 339555, and Cisplatin in Patients With Recurrent and/or Advanced Inoperable Squamous Cell, Adeno or Adenosquamous Cell Carcinoma of the Cervix Completed NCT00005965 Phase 2 bryostatin 1;cisplatin
36 Utility of Preoperative FDG-PET/CT Scanning Prior to Primary Chemoradiation Therapy to Detect Retroperitoneal Lymph Node Metastasis in Patients With Locoregionally Advanced Carcinoma of the Cervix (IB2, IIA ≥ 4 CM, IIB-IVA) or Endometrium (Grade 3 Endometrioid Endometrial Carcinoma; Serous Papillary Carcinoma, Clear Cell Carcinoma, or Carcinosarcoma (Any Grade); and Grade 1 OR 2 Endometrioid Endometrial Carcinoma With Cervical Stromal Involvement Overt in Clinical Examination or Confirmed by Endocervical Curettage Completed NCT00416455 Phase 1, Phase 2 ferumoxtran-10
37 A Phase II Study of Sunitinib (SU11248; NSC 736511) an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Patients With Unresectable, Locally Advanced or Metastatic Cervical Carcinoma Completed NCT00389974 Phase 2 sunitinib malate
38 A Phase II Study of CCI-779 in Patients With Metastatic and/or Locally Advanced Recurrent Endometrial Cancer Completed NCT00072176 Phase 2 temsirolimus
39 A Phase II Evaluation of Thalidomide (NSC #66847, IND 48832) in the Treatment of Recurrent of Persistent Endometrial Carcinoma Completed NCT00025467 Phase 2 thalidomide
41 The Potential for Metformin to Improve Tumor Oxygenation in Locally Advanced Cervix Cancer: A Phase II Randomized Trial Completed NCT02394652 Phase 2 Metformin;Cisplatin;FAZA
42 APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation Recruiting NCT04858334 Phase 2 Olaparib;Placebo Administration
43 A Phase II Trial of the Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP) Recruiting NCT04896073 Phase 2 Minnelide
44 Efficacy and Safety of Pemigatinib in Subjects With Advanced Metastatic or Surgically Unresectable Adenosquamous Carcinoma of the Pancreas (ASCP) Who Have Progressed On Previous Therapy Recruiting NCT05216120 Phase 2 Pemigatinib 4.5 MG
45 A Phase II Study Using Autologous Young Tumor-Infiltrating Lymphocytes Derived From Patients With Non-Small Cell Lung Cancer Following Non-Myeloablative Lymphocyte Depleting Preparative Regimen Recruiting NCT02133196 Phase 2 Aldesleukin;Fludarabine;Cyclophosphamide
46 An Open-label, Multicenter , Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 ( Recombinant Humanized Anti-EGFR Monoclonal Antibody Injection) Combination Therapy or Monotherapy in Patients With Locally Advanced, Unresectable or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) Recruiting NCT05221658 Phase 2 HLX07+HLX10+ Cisplatin+5-FU;HLX07
47 A Safety Lead in Single Arm Phase II Study for Image Guided Ultrafractionated Radiation Therapy for Treatment of Metastatic Cervical Cancer Recruiting NCT05021237 Phase 2
48 A Phase 2 Study of XL184 (Cabozantinib) in Recurrent or Metastatic Endometrial Cancer Active, not recruiting NCT01935934 Phase 2 Cabozantinib S-malate
49 A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer Active, not recruiting NCT02257528 Phase 2
50 A Three Arm Randomized Phase II Study of Paclitaxel/Carboplatin/Bevacizumab (NSC #704865), Paclitaxel/Carboplatin/Temsirolimus (NSC #683864) and Ixabepilone (NSC #710428)/Carboplatin/Bevacizumab as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer Active, not recruiting NCT00977574 Phase 2 Carboplatin;Ixabepilone;Paclitaxel;Temsirolimus

Search NIH Clinical Center for Adenosquamous Carcinoma

Cochrane evidence based reviews: carcinoma, adenosquamous

Genetic Tests for Adenosquamous Carcinoma

Anatomical Context for Adenosquamous Carcinoma

Organs/tissues related to Adenosquamous Carcinoma:

MalaCards : Pancreas, Cervix, Lung, Lymph Node, T Cells, Colon, Breast

Publications for Adenosquamous Carcinoma

Articles related to Adenosquamous Carcinoma:

(show top 50) (show all 2269)
# Title Authors PMID Year
Reclassifying bronchial-pulmonary carcinoma: differentiating histological type in biopsies by immunohistochemistry. 53 62
19859629 2009
Large cell carcinoma of the lung: an endangered species? 53 62
19444077 2009
Interferon-alpha conditioned sensitivity to an anti-epidermal growth factor receptor monoclonal antibody in a human lung cancer cell line with intermediate expression of the receptor. 53 62
19514842 2009
Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma. 53 62
19563658 2009
Adenosquamous carcinoma: a report of nine cases with p63 and cytokeratin 5/6 staining. 53 62
19278431 2009
Mucoepidermoid carcinoma of the lung, response to EGFR inhibitors, EGFR and K-RAS mutations, and differential diagnosis. 53 62
18992960 2009
Adenosquamous carcinoma of the pancreas associated with humoral hypercalcemia of malignancy (HHM). 53 62
18836809 2008
Cyclooxygenase-2 and epidermal growth factor receptor expressions in different histological subtypes of cervical carcinomas. 53 62
17581404 2007
Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung. 53 62
17186532 2007
Mucinous expression in benign and neoplastic glandular lesions of the uterine cervix. 53 62
17090193 2006
The correlation between TTF-1 immunoreactivity and the occurrence of lymph node metastases in patients with lung cancer. 53 62
17036524 2006
Mutations of epidermal growth factor receptor and K-ras genes in adenosquamous carcinoma of the lung. 53 62
16187277 2006
Paraneoplastic hypercalcemia with adenosquamous carcinoma of the colon. 53 62
15864702 2005
Unique characteristics of rectal carcinoma cell lines derived from invasive carcinomas in ulcerative colitis patients. 53 62
15016319 2004
Prospective evaluation of squamous cell carcinoma and carcinoembryonic antigen as prognostic factors in patients with cervical cancer. 53 62
14610320 2003
Colliding primary lung cancers of adenosquamous carcinoma and large cell neuroendocrine carcinoma. 53 62
12558872 2003
Neuroendocrine marker expression in cervical carcinomas of non-small cell type. 53 62
12352185 2002
Primary adenosquamous carcinoma of the liver which produces granulocyte-colony-stimulating factor and parathyroid hormone related protein: association with leukocytosis and hypercalcemia. 53 62
11506305 2001
Histologic and immunophenotypic classification of cervical carcinomas by expression of the p53 homologue p63: a study of 250 cases. 53 62
11381365 2001
Clinical value of tumor markers for early detection of recurrence in patients with cervical adenocarcinoma and adenosquamous carcinoma. 53 62
11006578 2000
EGF-dependent and independent programmed cell death pathways in NCI-H596 nonsmall cell lung cancer cells. 53 62
9588219 1998
Different angiogenic pathways in human cervical cancers. 53 62
9454658 1998
Surfactant protein gene expression in metastatic and micrometastatic pulmonary adenocarcinomas and other non-small cell lung carcinomas: detection by reverse transcriptase-polymerase chain reaction. 53 62
7671236 1995
Epidermal growth factor receptor (EGF-R) and transforming growth factor alpha (TGFA) expression in different endometrial cancers. 53 62
7654016 1995
Altered expression of nm23-H1 and c-erbB-2 proteins have prognostic significance in adenocarcinoma but not in squamous cell carcinoma of the uterine cervix. 53 62
7736397 1995
Hypercalcaemia in a patient with fatal adenosquamous carcinoma of the colon. 53 62
8107631 1994
Cathepsin-D expression in cervical carcinoma and its prognostic significance. 53 62
8322451 1993
Immunocytologic diagnosis of small-cell lung cancer in imprint smears. 53 62
1656682 1991
[A parathyroid hormone related protein (PTHrP) implicated in hypercalcemia associated with malignancy: research of the PTHrP for novel hormonal tumor marker]. 53 62
2348564 1990
Compressive optic neuropathy caused by sinonasal adenosquamous carcinoma with orbital extension: A case report. 62
36111279 2022
Single-cell RNA-sequencing dissects cellular heterogeneity and identifies two tumor-suppressing immune cell subclusters in HPV-related cervical adenosquamous carcinoma. 62
36000446 2022
Differences between complex epithelial neoplasms of the ovary and high-grade serous ovarian cancer: a retrospective observational cohort study. 62
36456989 2022
Correction to: Clinicopathological characteristics and prognosis of resectable lung adenosquamous carcinoma: a population-based study of the SEER database. 62
36125310 2022
Efficacy of chemotherapy for patients with metastatic or recurrent pancreatic adenosquamous carcinoma: A multicenter retrospective analysis. 62
36150984 2022
Clinical outcomes after positron emission tomography/computed tomography-based image-guided brachytherapy for cervical cancer. 62
35366364 2022
Histological patterns, subtypes and aspects of prostate cancer: different aspects, different outcomes. 62
36081403 2022
Long-term treatment outcomes/toxicities of definite chemoradiotherapy (intensity-modulated radiation therapy) for early-stage "bulky" cervical cancer and survival impact of histological subtype. 62
36379808 2022
The epidemiology of rare types of hepatobiliary and pancreatic cancer from national cancer registry. 62
36161533 2022
Adenosquamous Carcinoma of Extrahepatic Bile Duct in Primary Sclerosing Cholangitis. 62
36028730 2022
Progression of a persisting mesenchymal hamartoma to intrahepatic cholangiocarcinoma 24 years after the initial diagnosis: A case report. 62
35995570 2022
Primary lung carcinoma in children and adolescents: An analysis of the European Cooperative Study Group on Paediatric Rare Tumours (EXPeRT). 62
36087394 2022
Research advances and treatment perspectives of pancreatic adenosquamous carcinoma. 62
36316580 2022
Development of an adenosquamous carcinoma histo pathology-selective lung metastasis model. 62
36355420 2022
Peritoneal carcinomatosis after minimally invasive surgery versus open radical hysterectomy: systematic review and meta-analysis. 62
36351746 2022
Lacrimal sac ciliated HPV16 positive, adenosquamous carcinoma-A case report of a unique histological variant at this site and a review of the literature. 62
36398700 2022
Delayed local recurrence of pancreatic adenosquamous cell carcinoma after curative surgery: A case report. 62
36257141 2022
Pancreatic Adenosquamous Carcinoma: Experience Within an Integrated Health Care System. 62
36336674 2022
Molecular and expressional characterization of tumor heterogeneity in pulmonary carcinosarcoma. 62
35848137 2022
Adenosquamous carcinoma of the pancreas: two case reports and review of the literature. 62
36309754 2022
Clinicopathological characteristics and prognosis of resectable lung adenosquamous carcinoma: a population-based study of the SEER database. 62
35726160 2022

Variations for Adenosquamous Carcinoma

Expression for Adenosquamous Carcinoma

Search GEO for disease gene expression data for Adenosquamous Carcinoma.

Pathways for Adenosquamous Carcinoma

Pathways related to Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
Show member pathways
12.14 PGR KRT8 KRT7 KRT5 KRT19
Show member pathways
11.97 KRT8 KRT7 KRT5 KRT20 KRT19 IVL
3 11.59 MUC1 KRT8 KRT7 KRT5 KRT20 KRT19
Show member pathways
Show member pathways
11.38 MUC5AC MUC4 MUC1

GO Terms for Adenosquamous Carcinoma

Cellular components related to Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intermediate filament GO:0005882 9.32 KRT8 KRT7 KRT5 KRT20 KRT19

Biological processes related to Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 epidermis development GO:0008544 9.73 TP63 PTHLH KRT5 EGFR
2 epithelial cell differentiation GO:0030855 9.7 TP63 PGK1 KRT20 KRT19
3 positive regulation of phosphorylation GO:0042327 9.62 PDGFRA KDR EGFR
4 keratinization GO:0031424 9.56 KRT8 KRT7 KRT5 IVL
5 cell differentiation involved in embryonic placenta development GO:0060706 9.54 KRT8 KRT19
6 intermediate filament organization GO:0045109 9.32 KRT8 KRT7 KRT5 KRT20 KRT19

Molecular functions related to Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.73 PDGFRA KDR EGFR
2 vascular endothelial growth factor receptor activity GO:0005021 9.46 PDGFRA KDR
3 vascular endothelial growth factor binding GO:0038085 9.26 PDGFRA KDR
4 structural constituent of skin epidermis GO:0030280 9.1 KRT8 KRT7 KRT5

Sources for Adenosquamous Carcinoma

8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
27 GO
28 GTR
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
36 LifeMap
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....